AstraZeneca Talks Up US Growth as China Problems Fester
AstraZeneca Plc is increasingly looking to the US for growth as its once fast-expanding China business faces challenges amid a probe that has battered the drugmaker’s share price.
AstraZeneca says detained China head has lawyer, but company still in dark
London-listed drugmaker AstraZeneca said its plan to invest 450 million pounds ($576.7 million) in Britain for vaccine research and development, announced in March, is on hold while talks with the UK government continue.
AstraZeneca chief says group takes China probe ‘very seriously’
AstraZeneca chief executive Pascal Soriot said the company took the detention of its China president “very seriously”, as the drugmaker raised its guidance for a second straight quarter on the back of strong sales of cancer medicines.
Pharma Giant AstraZeneca Takes China Probes 'Very Seriously'
British pharmaceutical giant AstraZeneca on Tuesday said it takes "very seriously" China's investigations into potential illegal data collection and drug imports by the group that caused the detention of its China boss.
AstraZeneca CEO says detained China chief has a lawyer but 'we have no information'
AstraZeneca's CEO said on Tuesday that the company's China president Leon Wang, who last month was detained by Chinese authorities, has a lawyer he is in touch with, but "we have no information as a company".
AstraZeneca lifts 2024 outlook after Q3 beat, doubles down on US investments
Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time this year on Tuesday, helped by strong ...
Hosted on MSN19h
AstraZeneca Expands U.S. Investment Plan
AstraZeneca said it plans to pump $2 billion in new investment into the U.S., one of the first major foreign companies to ...
STAT19h
Pharmalittle: We’re reading about 23andMe retrenching, AstraZeneca reworking cancer drug plans, and more
In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...
MM&M12h
AstraZeneca: New drug data, promising earnings and a $3.5B R&D investment
AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...
AstraZeneca Reports Strong Growth in Q3 2024
AstraZeneca ( (AZN) ) has released its Q3 earnings. Here is a breakdown of the information AstraZeneca presented to its investors. AstraZeneca ...
STAT23h
AstraZeneca, Daiichi Sankyo change strategy on closely watched cancer drug
LONDON — AstraZeneca said Tuesday it has had to resubmit a closely watched medicine for U.S. approval in a different form of ...
Benzinga.com19h
AstraZeneca Lifts 2024 Forecast On Better Than Expected Q3 Performance, Says It Takes China Investigations 'Very Seriously'
AstraZeneca's Q3 sales rose 18% YoY to $13.6 billion Adjusted EPADS hit $1.04, exceeding expectations. U.S. investment of ...
Yahoo Finance2h
AstraZeneca PLC (AZN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
Full Year Guidance Upgrade (2024): Total revenue and core EPS expected to grow by high 10s percentage. AstraZeneca PLC ...
BioSpace16h
AstraZeneca Dodges China Questions While Raising 2024 Outlook With Strong Q3 Sales
The U.K. drugmaker also announced plans to drop another $2 billion on expanding its R&D and manufacturing footprint in the ...
Wall Street Journal1d
AstraZeneca Raises Outlook on Earnings, Sales Beat
AstraZeneca AZN0.83%increase; green up pointing triangle raised its full-year guidance after third-quarter revenue and core ...
The Washington Post23h
Astrazeneca: Q3 Earnings Snapshot
CAMBRIDGE, Britain — CAMBRIDGE, Britain — Astrazeneca PLC (AZN) on Tuesday reported third-quarter earnings of $1.43 billion. On a per-share basis, the Cambridge, Britain-based company said it had ...